Human CD56bright NK cells: An update

Journal of Immunology

Volumn 196, Issue 7, 2016, Pages 2923-2931

  Michel, Tatiana ^a   Poli, Aurélie ^a   Cuapio, Angelica ^b   Briquemont, Benjamin ^a   Iserentant, Gilles ^a   Ollert, Markus ^a,c   Zimmer, Jacques ^a  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; DACLIZUMAB; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; IPILIMUMAB; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL KILLER CELL RECEPTOR NKG2D; TRANSCRIPTION FACTOR GATA 2;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL LINEAGE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOREGULATION; INNATE IMMUNITY; JUVENILE DERMATOMYOSITIS; LUNG CANCER; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MELANOMA; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TRAUMATIC BRAIN INJURY; TUMOR VOLUME; UPREGULATION; VIRUS ENTRY; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; CYTOTOXICITY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE SUBPOPULATION; METABOLISM;

ANIMALS; ANTIGENS, CD56; CELL DIFFERENTIATION; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; PHENOTYPE;

EID: 84962579545     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1502570     Document Type: Review

References (109)

1. Poli, A., T. Michel, M. Thérésine, E. Andrès, F. Hentges, and J. Zimmer. 2009. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 126:458-465.
2. Cooper, M. A., T. A. Fehniger, and M. A. Caligiuri. 2001. The biology of human natural killer-cell subsets. Trends Immunol. 22:633-640.
3. Freud, A. G., J. Yu, and M. A. Caligiuri. 2014. Human natural killer cell development in secondary lymphoid tissues. Semin. Immunol. 26:132-137.
4. Luetke-Eversloh, M., M. Killig, and C. Romagnani. 2013. Signatures of human NK cell development and terminal differentiation. Front. Immunol. 4:499.
5. Berrien-Elliott, M. M., J. A. Wagner, and T. A. Fehniger. 2015. Human Cytokine-Induced Memory-Like Natural Killer Cells. J. Innate Immun. 7:563-571.
6. Mace, E. M., A. P. Hsu, L. Monaco-Shawver, G. Makedonas, J. B. Rosen, L. Dropulic, J. I. Cohen, E. P. Frenkel, J. C. Bagwell, J. L. Sullivan, et al. 2013. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56 (bright) subset. Blood 121:2669-2677.
7. Maciejewski-Duval, A., F. Meuris, A. Bignon, M. L. Aknin, K. Balabanian, L. Faivre, M. Pasquet, V. Barlogis, C. Fieschi, C. Bellanné-Chantelot, et al. 2015. Altered chemotactic response to CXCL12 in patients carrying GATA2 mutations. J. Leukoc. Biol. DOI:10.1189/jlb.5MA0815-388R.
8. Gineau, L., C. Cognet, N. Kara, F. P. Lach, J. Dunne, U. Veturi, C. Picard, C. Trouillet, C. Eidenschenk, S. Aoufouchi, et al. 2012. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J. Clin. Invest. 122:821-832.
9. Wu, C., B. Li, R. Lu, S. J. Koelle, Y. Yang, A. Jares, A. E. Krouse, M. Metzger, F. Liang, K. Loré, et al. 2014. Clonal tracking of rhesus macaque hematopoiesis highlights a distinct lineage origin for natural killer cells. Cell Stem Cell 14:486-499.
10. Dykstra, B., and L. V. Bystrykh. 2014. No monkeying around: clonal tracking of stem cells and progenitors in the macaque. Cell Stem Cell 14:419-420.
11. Diefenbach, A., M. Colonna, and S. Koyasu. 2014. Development, differentiation, and diversity of innate lymphoid cells. Immunity 41:354-365.
12. Artis, D., and H. Spits. 2015. The biology of innate lymphoid cells. Nature 517:293-301.
13. Eberl, G., M. Colonna, J. P. Di Santo, and A. N. McKenzie. 2015. Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology. Science 348: aaa6566.
14. Grzywacz, B., N. Kataria, N. Kataria, B. R. Blazar, J. S. Miller, and M. R. Verneris. 2011. Natural killer-cell differentiation by myeloid progenitors. Blood 117:3548-3558.
15. Chen, Q., W. Ye, W. Jian Tan, K. S. Mei Yong, M. Liu, S. Qi Tan, E. Loh, K. Te Chang, T. Chye Tan, P. R. Preiser, and J. Chen. 2015. Delineation of Natural Killer Cell Differentiation from Myeloid Progenitors in Human. Sci. Rep. 5:15118.
16. Milush, J. M., B. R. Long, J. E. Snyder-Cappione, A. J. Cappione, III, V. A. York, L. C. Ndhlovu, L. L. Lanier, J. Michaëlsson, and D. F. Nixon. 2009. Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. Blood 114:4823-4831.
17. Schlums, H., F. Cichocki, B. Tesi, J. Theorell, V. Beziat, T. D. Holmes, H. Han, S. C. Chiang, B. Foley, K. Mattsson, et al. 2015. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 42:443-456.
18. Lee, J., T. Zhang, I. Hwang, A. Kim, L. Nitschke, M. Kim, J. M. Scott, Y. Kamimura, L. L. Lanier, and S. Kim. 2015. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity 42:431-442.
19. Cichocki, F., J. S. Miller, S. K. Anderson, and Y. T. Bryceson. 2013. Epigenetic regulation of NK cell differentiation and effector functions. Front. Immunol. 4:55.
20. Angelo, L. S., P. P. Banerjee, L. Monaco-Shawver, J. B. Rosen, G. Makedonas, L. R. Forbes, E. M. Mace, and J. S. Orange. 2015. Practical NK cell phenotyping and variability in healthy adults. Immunol. Res. 62:341-356.
21. Sanchez-Correa, B., C. Campos, A. Pera, J. M. Bergua, M. J. Arcos, H. Bañas, J. G. Casado, S. Morgado, E. Duran, R. Solana, and R. Tarazona. 2015. Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies? Cancer Immunol. Immunother. DOI: 10.1007/s00262-015-1720-6.
22. Bauernhofer, T., I. Kuss, B. Henderson, A. S. Baum, and T. L. Whiteside. 2003. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur. J. Immunol. 33:119-124.
23. Wulff, S., R. Pries, K. Börngen, T. Trenkle, and B. Wollenberg. 2009. Decreased levels of circulating regulatory NK cells in patients with head and neck cancer throughout all tumor stages. Anticancer Res. 29:3053-3057.
24. Klöß, S., N. Chambron, T. Gardlowski, L. Arseniev, J. Koch, R. Esser, W. Glienke, O. Seitz, and U. Köhl. 2015. Increased sMICA and TGFb1 levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells. Oncoimmunology 4:e1055993.
25. Mamessier, E., L. C. Pradel, M. L. Thibult, C. Drevet, A. Zouine, J. Jacquemier, G. Houvenaeghel, F. Bertucci, D. Birnbaum, and D. Olive. 2013. Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. J. Immunol. 190:2424-2436.
26. Stabile, H., P. Nisti, S. Morrone, D. Pagliara, A. Bertaina, F. Locatelli, A. Santoni, and A. Gismondi. 2015. Multifunctional human CD56 low CD16 low natural killer cells are the prominent subset in bone marrow of both healthy pediatric donors and leukemic patients. Haematologica 100:489-498.
27. Ali, T. H., S. Pisanti, E. Ciaglia, R. Mortarini, A. Anichini, C. Garofalo, R. Tallerico, M. Santinami, E. Gulletta, C. Ietto, et al. 2014. Enrichment of CD56 (dim) KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nat. Commun. 5:5639.
28. Holtan, S. G., D. J. Creedon, M. A. Thompson, W. K. Nevala, and S. N. Markovic. 2011. Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanoma. Clin. Dev. Immunol. 2011:316314.
29. Belisle, J. A., J. A. Gubbels, C. A. Raphael, M. Migneault, C. Rancourt, J. P. Connor, and M. S. Patankar. 2007. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 122:418-429.
30. Carlsten, M., H. Norell, Y. T. Bryceson, I. Poschke, K. Schedvins, H. G. Ljunggren, R. Kiessling, and K. J. Malmberg. 2009. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J. Immunol. 183:4921-4930.
31. Pesce, S., G. Tabellini, C. Cantoni, O. Patrizi, D. Coltrini, F. Rampinelli, J. Matta, E. Vivier, A. Moretta, S. Parolini, and E. Marcenaro. 2015. B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. OncoImmunology 4:e1001224.
32. Watanabe, M., K. Kono, Y. Kawaguchi, Y. Mizukami, K. Mimura, T. Maruyama, S. Izawa, and H. Fujii. 2010. NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma. Dis. Esophagus 23:675-681.
33. McInnes, I. B., and G. Schett. 2011. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365:2205-2219.
34. Ahern, D. J., and F. M. Brennan. 2011. The role of Natural Killer cells in the pathogenesis of rheumatoid arthritis: major contributors or essential homeostatic modulators? Immunol. Lett. 136:115-121.
35. Conigliaro, P., R. Scrivo, G. Valesini, and R. Perricone. 2011. Emerging role for NK cells in the pathogenesis of inflammatory arthropathies. Autoimmun. Rev. 10:577-581.
36. Pridgeon, C., G. P. Lennon, L. Pazmany, R. N. Thompson, S. E. Christmas, and R. J. Moots. 2003. Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit a CD56bright, CD94bright, CD158negative phenotype. Rheumatology (Oxford) 42:870-878.
37. Dalbeth, N., and M. F. Callan. 2002. A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum. 46:1763-1772.
38. Dalbeth, N., R. Gundle, R. J. Davies, Y. C. Lee, A. J. McMichael, and M. F. Callan. 2004. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J. Immunol. 173:6418-6426.
39. Daïen, C. I., S. Gailhac, R. Audo, T. Mura, M. Hahne, B. Combe, and J. Morel. 2015. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis. Rheumatology (Oxford) 54:601-608.
40. Burke, S. D., A. V. Seaward, H. Ramshaw, G. N. Smith, S. Virani, B. A. Croy, and P. D. Lima. 2015. Homing receptor expression is deviated on CD56+ blood lymphocytes during pregnancy in Type 1 diabetic women. PLoS One 10:e0119526.
41. Seaward, A. V., S. D. Burke, H. Ramshaw, G. N. Smith, and B. A. Croy. 2011. Circulating CD56+ cells of diabetic women show deviated homing potential for specific tissues during and following pregnancy. Hum. Reprod. 26:1675-1684.
42. Schepis, D., I. Gunnarsson, M. L. Eloranta, J. Lampa, S. H. Jacobson, K. Kärre, and L. Berg. 2009. Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology 126:140-146.
43. Hervier, B., V. Beziat, J. Haroche, A. Mathian, P. Lebon, P. Ghillani-Dalbin, L. Musset, P. Debré, Z. Amoura, and V. Vieillard. 2011. Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-γ production in patients with active disease. Arthritis Rheum. 63:1698-1706.
44. Rusakiewicz, S., G. Nocturne, T. Lazure, M. Semeraro, C. Flament, S. Caillat-Zucman, D. Sène, N. Delahaye, E. Vivier, K. Chaba, et al. 2013. NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome. Sci. Transl. Med. 5:195ra96.
45. Ernste, F. C., C. S. Crowson, C. L. De Padilla, M. S. Hein, and A. M. Reed. 2013. Longitudinal peripheral blood lymphocyte subsets correlate with decreased disease activity in juvenile dermatomyositis. J. Rheumatol. 40:1200-1211.
46. Almeida, I., S. V. Silva, A. R. Fonseca, I. Silva, C. Vasconcelos, and M. Lima. 2015. T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review. Clin. Rev. Allergy Immunol. 49:347-369.
47. Bielekova, B., N. Richert, M. L. Herman, J. Ohayon, T. A. Waldmann, H. McFarland, R. Martin, and G. Blevins. 2011. Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology 77:1877-1886.
48. Martínez-Rodríguez, J. E., M. López-Botet, E. Munteis, J. Rio, J. Roquer, X. Montalban, and M. Comabella. 2011. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clin. Immunol. 141:348-356.
49. Skarica, M., C. Eckstein, K. A. Whartenby, and P. A. Calabresi. 2011. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J. Neuroimmunol. 235:70-76.
50. Johnson, T. A., B. L. Evans, B. A. Durafourt, M. Blain, Y. Lapierre, A. Bar-Or, and J. P. Antel. 2011. Reduction of the peripheral blood CD56 (bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients. J. Immunol. 187:570-579.
51. Mehling, M., A. V. Burgener, V. Brinkmann, G. R. Bantug, S. Dimeloe, G. Hoenger, L. Kappos, and C. Hess. 2015. Tissue Distribution Dynamics of Human NK Cells Inferred from Peripheral Blood Depletion Kinetics after Sphingosine-1-Phosphate Receptor Blockade. Scand. J. Immunol. 82:460-466.
52. Airas, L., M. Saraste, S. Rinta, I. Elovaara, Y. H. Huang, and H. Wiendl, Finnish Multiple Sclerosis and Pregnancy Study Group. 2008. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin. Exp. Immunol. 151:235-243.
53. Mrakovcic-Sutic, I., V. S. Tokmadzic, G. Laskarin, H. Mahmutefendic, P. Lucin, Z. Zupan, and A. Sustic. 2010. Early changes in frequency of peripheral blood lymphocyte subpopulations in severe traumatic brain-injured patients. Scand. J. Immunol. 72:57-65.
54. Mantegani, P., G. Tambussi, L. Galli, C. T. Din, A. Lazzarin, and C. Fortis. 2010. Perturbation of the natural killer cell compartment during primary human immunodeficiency virus 1 infection primarily involving the CD56 bright subset. Immunology 129:220-233.
55. Cichocki, F., H. Schlums, J. Theorell, B. Tesi, J. S. Miller, H. G. Ljunggren, and Y. T. Bryceson. 2015. Diversification and Functional Specialization of Human NK Cell Subsets. Curr. Top. Microbiol. Immunol. 395:63-93.
56. Hudspeth, K., M. Donadon, M. Cimino, E. Pontarini, P. Tentorio, M. Preti, M. Hong, A. Bertoletti, S. Bicciato, P. Invernizzi, et al. 2016. Human liver-resident CD56 (bright)/CD16 (neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. J. Autoimmun. 66:40-50.
57. + hematopoietic precursors are present in human decidua and differentiate into natural killer cells upon interaction with stromal cells. Proc. Natl. Acad. Sci. USA 108:2402-2407.
58. Tabellini, G., M. Benassi, E. Marcenaro, D. Coltrini, O. Patrizi, D. Ricotta, F. Rampinelli, A. Moretta, and S. Parolini. 2014. Primitive neuroectodermal tumor in an ovarian cystic teratoma: natural killer and neuroblastoma cell analysis. Case Rep. Oncol. 7:70-78.
59. Lukesova, S., V. Vroblova, J. Tosner, J. Kopecky, I. Sedlakova, E. Ćermáková, D. Vokurkova, and O. Kopecky. 2015. Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma. Contemp. Oncol. (Pozn.) 19:290-299.
60. Levi, I., H. Amsalem, A. Nissan, M. Darash-Yahana, T. Peretz, O. Mandelboim, and J. Rachmilewitz. 2015. Characterization of tumor infiltrating natural killer cell subset. Oncotarget 6:13835-13843.
61. Vacca, P., S. Martini, V. Garelli, G. Passalacqua, L. Moretta, and M. C. Mingari. 2013. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation. Eur. J. Immunol. 43:550-561.
62. Pokkali, S., S. D. Das, and A. Selvaraj. 2009. Differential upregulation of chemokine receptors on CD56 NK cells and their transmigration to the site of infection in tuberculous pleurisy. FEMS Immunol. Med. Microbiol. 55:352-360.
63. Luci, C., C. Gaudy-Marqueste, P. Rouzaire, S. Audonnet, C. Cognet, A. Hennino, J. F. Nicolas, J. J. Grob, and E. Tomasello. 2012. Peripheral natural killer cells exhibit qualitative and quantitative changes in patients with psoriasis and atopic dermatitis. Br. J. Dermatol. 166:789-796.
64. Ottaviani, C., F. Nasorri, C. Bedini, O. De Pità, G. Girolomoni, and A. Cavani. 2006. CD56brightCD16 (2) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur. J. Immunol. 36:118-128.
65. Han, S., Y. C. Lin, T. Wu, A. D. Salgado, I. Mexhitaj, S. C. Wuest, E. Romm, J. Ohayon, R. Goldbach-Mansky, A. Vanderver, et al. 2014. Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases. J. Immunol. 192:2551-2563.
66. Rodríguez-Martín, E., C. Picón, L. Costa-Frossard, R. Alenda, S. Sainz De La Maza, E. Roldán, M. Espiño, L. M. Villar, and J. C. Álvarez-Cermeño. 2015. Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis. Clin. Exp. Immunol. 180:243-249.
67. Poli, A., J. Kmiecik, O. Domingues, F. Hentges, M. Bléry, M. Chekenya, J. Boucraut, and J. Zimmer. 2013. NK cells in central nervous system disorders. J. Immunol. 190:5355-5362.
68. Teunissen, C., T. Menge, A. Altintas, J. C. Álvarez-Cermeño, A. Bertolotto, F. S. Berven, L. Brundin, M. Comabella, M. Degn, F. Deisenhammer, et al. 2013. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult. Scler. 19:1802-1809.
69. Lin, Y. C., P. Winokur, A. Blake, T. Wu, E. Romm, and B. Bielekova. 2015. Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis. Ann. Clin. Transl. Neurol. 2:445-455.
70. Hao, J., R. Liu, W. Piao, Q. Zhou, T. L. Vollmer, D. I. Campagnolo, R. Xiang, A. La Cava, L. Van Kaer, and F. D. Shi. 2010. Central nervous system (CNS) - resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J. Exp. Med. 207:1907-1921.
71. Hao, J., D. Campagnolo, R. Liu, W. Piao, S. Shi, B. Hu, R. Xiang, Q. Zhou, T. Vollmer, L. Van Kaer, et al. 2011. Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann. Neurol. 69:721-734.
72. Béziat, V., D. Duffy, S. N. Quoc, M. Le Garff-Tavernier, J. Decocq, B. Combadière, P. Debré, and V. Vieillard. 2011. CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation. J. Immunol. 186:6753-6761.
73. Delahaye, N. F., S. Rusakiewicz, I. Martins, C. Ménard, S. Roux, L. Lyonnet, P. Paul, M. Sarabi, N. Chaput, M. Semeraro, et al. 2011. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat. Med. 17:700-707.
74. Mamessier, E., A. Sylvain, M. L. Thibult, G. Houvenaeghel, J. Jacquemier, R. Castellano, A. Gonçalves, P. André, F. Romagné, G. Thibault, et al. 2011. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J. Clin. Invest. 121:3609-3622.
75. Carrega, P., B. Morandi, R. Costa, G. Frumento, G. Forte, G. Altavilla, G. B. Ratto, M. C. Mingari, L. Moretta, and G. Ferlazzo. 2008. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16 (-) cells and display an impaired capability to kill tumor cells. Cancer 112:863-875.
76. Messaoudene, M., G. Fregni, E. Fourmentraux-Neves, J. Chanal, E. Maubec, S. Mazouz-Dorval, B. Couturaud, A. Girod, X. Sastre-Garau, S. Albert, et al. 2014. Mature cytotoxic CD56 (bright)/CD16 (+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. Cancer Res. 74:81-92.
77. Yu, J., H. C. Mao, M. Wei, T. Hughes, J. Zhang, I. K. Park, S. Liu, S. McClory, G. Marcucci, R. Trotta, and M. A. Caligiuri. 2010. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood 115:274-281.
78. Takahashi, E., N. Kuranaga, K. Satoh, Y. Habu, N. Shinomiya, T. Asano, S. Seki, and M. Hayakawa. 2007. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD162 CD56bright NK Cells but also from CD162 CD56dim NK cells. Scand. J. Immunol. 65:126-138.
79. Johnson, D. B., and J. A. Sosman. 2015. Therapeutic Advances and Treatment Options in Metastatic Melanoma. JAMA Oncol. 1:380-386.
80. Tallerico, R., C. M. Cristiani, M. Capone, G. Madonna, D. Mallardo, E. Simeone, A. Dominijanni, A. M. Grimaldi, F. Colucci, P. A. Ascierto, and E. Carbone. 2015. Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients. J. Transl. Med. 13(Suppl.1):O8.
81. De Matos, C. T., L. Berg, J. Michaëlsson, L. Felländer-Tsai, K. Kärre, and K. Söderström. 2007. Activating and inhibitory receptors on synovial fluid natural killer cells of arthritis patients: role of CD94/NKG2A in control of cytokine secretion. Immunology 122:291-301.
82. Nielsen, N., V. Pascal, A. E. Fasth, Y. Sundström, E. D. Galsgaard, D. Ahern, M. Andersen, B. Baslund, E. M. Bartels, H. Bliddal, et al. 2014. Balance between activating NKG2D, DNAM-1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts. Immunology 142:581-593.
83. Cerboni, C., M. Mousavi-Jazi, H. Wakiguchi, E. Carbone, K. Kärre, and K. Söderström. 2001. Synergistic effect of IFN-gamma and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cell-mediated cytotoxicity. Eur. J. Immunol. 31:2926-2935.
84. Spear, P., M. R. Wu, M. L. Sentman, and C. L. Sentman. 2013. NKG2D ligands as therapeutic targets. Cancer Immun. 13:8.
85. Zingoni, A., M. Ardolino, A. Santoni, and C. Cerboni. 2012. NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses. Front. Immunol. 3:408.
86. Söderström, K., E. Stein, P. Colmenero, U. Purath, U. Müller-Ladner, C. T. De Matos, I. H. Tarner, W. H. Robinson, and E. G. Engleman. 2010. Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc. Natl. Acad. Sci. USA 107:13028-13033.
87. Takayanagi, H., H. Iizuka, T. Juji, T. Nakagawa, A. Yamamoto, T. Miyazaki, Y. Koshihara, H. Oda, K. Nakamura, and S. Tanaka. 2000. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 43:259-269.
88. Tanaka, S. 2013. Regulation of bone destruction in rheumatoid arthritis through RANKL-RANK pathways. World J. Orthop. 4:1-6.
89. Huth, T. K., E. W. Brenu, S. Ramos, T. Nguyen, S. Broadley, D. Staines, and S. Marshall-Gradisnik. 2016. Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis. Scand. J. Immunol. 83:44-51.
90. Hardcastle, S. L., E. W. Brenu, S. Johnston, T. Nguyen, T. Huth, S. Ramos, D. Staines, and S. Marshall-Gradisnik. 2015. Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. J. Transl. Med. 13:299.
91. Brenu, E. W., M. L. Van Driel, D. R. Staines, K. J. Ashton, S. B. Ramos, J. Keane, N. G. Klimas, and S. M. Marshall-Gradisnik. 2011. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J. Transl. Med. 9:81.
92. Frias, M., A. Rivero-Juarez, A. Gordon, A. Camacho, S. Cantisan, F. Cuenca-Lopez, J. Torre-Cisneros, J. Peña, and A. Rivero. 2015. Persistence of pathological distribution of NK cells in HIV-infected patients with prolonged use of HAART and a sustained immune response. PLoS One 10:e0121019.
93. + T-cells in a hemophiliac HIV/HCV co-infected patient without opportunistic infections. Virol. J. 10:33.
94. Weiss, I. D., H. Shoham, O. Wald, H. Wald, K. Beider, M. Abraham, N. Barashi, E. Galun, A. Nagler, and A. Peled. 2011. Ccr5 deficiency regulates the proliferation and trafficking of natural killer cells under physiological conditions. Cytokine 54:249-257.
95. + T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A. PLoS One 7:e31959.
96. + T Cell Proliferation. J. Immunol. 195:965-972.
97. Chalifour, A., P. Jeannin, J. F. Gauchat, A. Blaecke, M. Malissard, T. N'Guyen, N. Thieblemont, and Y. Delneste. 2004. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood 104:1778-1783.
98. Batoni, G., S. Esin, F. Favilli, M. Pardini, D. Bottai, G. Maisetta, W. Florio, and M. Campa. 2005. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin. Scand. J. Immunol. 62:498-506.
99. Schierloh, P., N. Yokobori, M. Alemán, R. M. Musella, M. Beigier-Bompadre, M. A. Saab, L. Alves, E. Abbate, S. S. De La Barrera, and M. C. Sasiain. 2005. Increased susceptibility to apoptosis of CD56dimCD16+ NK cells induces the enrichment of IFN-gamma-producing CD56bright cells in tuberculous pleurisy. J. Immunol. 175:6852-6860.
100. Souza-Fonseca-Guimaraes, F., M. Parlato, F. Philippart, B. Misset, J. M. Cavaillon, and M. Adib-Conquy, Captain study group. 2012. Toll-like receptors expression and interferon-γ production by NK cells in human sepsis. Crit. Care 16:R206.
101. Boomer, J. S., J. Shuherk-Shaffer, R. S. Hotchkiss, and J. M. Green. 2012. A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit. Care 16:R112.
102. Reinhardt, R., S. Pohlmann, H. Kleinertz, M. Hepner-Schefczyk, A. Paul, and S. B. Flohé. 2015. Invasive Surgery Impairs the Regulatory Function of Human CD56 bright Natural Killer Cells in Response to Staphylococcus aureus. Suppression of Interferon-γ Synthesis. PLoS One 10:e0130155.
103. Martin, R. 2012. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin. Immunol. 142:9-14.
104. Kaur, G., J. Trowsdale, and L. Fugger. 2013. Natural killer cells and their receptors in multiple sclerosis. Brain 136:2657-2676.
105. Elkins, J., J. Sheridan, L. Amaravadi, K. Riester, K. Selmaj, B. Bielekova, E. Parr, and G. Giovannoni. 2015. CD56 (bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS. Neurol. Neuroimmunol. Neuroinflamm. 2:e65.
106. Martin, J. F., J. S. Perry, N. R. Jakhete, X. Wang, and B. Bielekova. 2010. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56 (bright) NK cells. J. Immunol. 185:1311-1320.
107. Jiang, W., N. R. Chai, D. Maric, and B. Bielekova. 2011. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J. Immunol. 187:781-790.
108. Sheridan, J. P., Y. Zhang, K. Riester, M. T. Tang, L. Efros, J. Shi, J. Harris, V. Vexler, and J. S. Elkins. 2011. Intermediate-affinity interleukin-2 receptor expression predicts CD56 (bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis. Mult. Scler. 17:1441-1448.
109. Wynn, D., M. Kaufman, X. Montalban, T. Vollmer, J. Simon, J. Elkins, G. O'Neill, L. Neyer, J. Sheridan, C. Wang, et al; CHOICE investigators. 2010. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 9:381-390.